The Garden Daisy That STOPS Migraines. Grows for Free. Why Won’t Doctors Prescribe It?

Summary

The video tells the story of feverfew (Tanacetum parthenium), a daisy-like garden plant with a long history as a traditional remedy for headaches. It describes an anecdote from a mining community in South Wales: a woman reportedly ate a few leaves daily and experienced fewer migraines. That story prompted London doctor E. Stuart Johnson to investigate.

The video traces feverfew’s history from ancient Greek and medieval herbal traditions—where it was used for fever, pain, swelling, and headaches—to its later status as an ornamental plant. It suggests that the arrival of standardized, patentable painkillers helped push the home-grown remedy out of mainstream use.

Research and proposed mechanism

• Johnson first surveyed 270 people who had used feverfew for migraines. About seven in ten reportedly said their attacks became less frequent or less severe.
• In 1985, Johnson and colleagues published a double-blind study in the British Medical Journal. Participants who continued taking feverfew reportedly remained stable, while those switched to placebo without their knowledge experienced more frequent or severe migraines.
• A second double-blind study, published in The Lancet in 1988 by researchers from the University of Nottingham, reportedly found fewer and milder attacks among people taking feverfew than among those taking placebo.
• Researcher Stephen Heptinstall’s laboratory work identified parthenolide, a compound in feverfew, as a possible contributor to its effects. The video says it may affect serotonin release from platelets and reduce some inflammatory signals associated with migraine.
• The video emphasizes that the studies discussed feverfew as a preventive treatment taken regularly, not as a remedy to take once a migraine has already begun. It also reports that chewing raw leaves can cause mouth ulcers in some people.
• A 2015 Cochrane review is described as finding the evidence promising but calling for larger, better studies. The video also mentions a 2005 German trial of a standardized feverfew extract that reportedly found fewer migraine attacks.

The video argues that limited commercial incentive may help explain why feverfew has not become a mainstream treatment: a plant that can be grown from seed is difficult to patent. This is presented as an explanation, not as demonstrated proof of the cause.

Plant-name clarification: The subtitles sometimes call the plant “tansy,” “pyrethrum,” or “maidenhair fern,” and once refer to chamomile. These appear to be transcription or naming errors. The plant discussed is feverfew (Tanacetum parthenium), not maidenhair fern. Common names such as “tansy” can also refer to different plants. The research described does not establish feverfew as a cure, and the video itself notes that more rigorous evidence is needed.

Researchers and sources mentioned

• E. Stuart Johnson — investigated reports of feverfew use and led the 1985 study.
• Stephen Heptinstall — studied feverfew’s active compounds, including parthenolide.
• University of Nottingham research team — conducted the later double-blind study.
• Dioscorides — ancient physician cited for recommending the plant.
• John Gerard — English herbalist whose 1597 work is cited.
• British Medical Journal — published the 1985 study.
• The Lancet — published the later study.
• Cochrane review (2015) — reviewed the evidence and called for larger, better studies.
• German clinical trial (2005) — cited as testing a standardized feverfew extract.